---
title: "Celcuity Inc. (CELC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CELC.US.md"
symbol: "CELC.US"
name: "Celcuity Inc."
industry: "Biotechnology"
datetime: "2026-04-15T04:35:17.793Z"
locales:
  - [en](https://longbridge.com/en/quote/CELC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CELC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CELC.US.md)
---

# Celcuity Inc. (CELC.US)

## Company Overview

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company’s lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.celcuity.com](https://www.celcuity.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -32.99 | 521 | - | - | - |
| PB | 58.09 | 442 | 49.66 | 41.34 | 5.64 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-08T04:00:00.000Z

Total Analysts: **11**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 9 | 82% |
| Overweight | 1 | 9% |
| Hold | 1 | 9% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 120.85 |
| Highest Target | 155.00 |
| Lowest Target | 94.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CELC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CELC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CELC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/CELC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**